3,176 Shares in AbbVie Inc. $ABBV Purchased by Portus Wealth Advisors LLC

Portus Wealth Advisors LLC bought a new stake in AbbVie Inc. (NYSE:ABBV) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,176 shares of the company’s stock, valued at approximately $735,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its position in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the period. Nordwand Advisors LLC grew its position in AbbVie by 9,478.0% during the 2nd quarter. Nordwand Advisors LLC now owns 46,166 shares of the company’s stock worth $8,569,000 after purchasing an additional 45,684 shares during the period. Finally, Frank Rimerman Advisors LLC raised its stake in shares of AbbVie by 15.5% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 31,907 shares of the company’s stock valued at $5,923,000 after buying an additional 4,291 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.08% of the company’s stock.

AbbVie Price Performance

ABBV opened at $219.96 on Wednesday. The firm has a market capitalization of $388.92 billion, a price-to-earnings ratio of 93.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. The company’s 50 day simple moving average is $224.27 and its two-hundred day simple moving average is $224.95. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s payout ratio is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year agreement with AbbVie to develop a next‑generation antibody discovery platform; Alloy will receive an upfront payment plus milestones, which can accelerate discovery of hard‑to‑drug targets and provide non‑dilutive near‑term cash. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: William Blair reiterated confidence in AbbVie’s growth prospects tied to obesity treatment progress after positive Phase 1 results — this underscores potential upside from a new high‑growth therapeutic area beyond core franchises. William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) launched a Skin Quality Index to standardize patient/provider conversations in aesthetics — a marketing and product‑positioning move that can support elective‑procedure demand and cross‑sell across Allergan’s portfolio. AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
• Positive Sentiment: Notable institutional interest: Billionaire Ken Fisher’s fund has included AbbVie among its notable 2026 moves, signaling confidence from an established investor and potential buying support. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Neutral Sentiment: Zacks and other analysts highlight AbbVie as a strong value stock based on valuation metrics and steady cash flows — useful context for longer‑term investors but not an immediate price catalyst. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: A U.S. appeals court revived a whistleblower lawsuit alleging overcharging on drugs for low‑income patients against several large drugmakers, creating a sector‑level legal overhang; it’s unclear from published reports whether AbbVie is a named defendant, but the ruling increases regulatory/legal risk for big pharma generally. Big drugmakers must face US overcharge claims on medications for low-income patients
• Negative Sentiment: Technical pressure — several market writeups note ABBV has slipped below its 50‑day simple moving average, signaling short‑term momentum weakness and prompting traders to take profits or wait for a dip to re‑enter. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. Piper Sandler boosted their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Finally, Morgan Stanley raised their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.